# SAM #SPE2DP-26-D-0001

DLA Troop Support Seeks Antidote Treatment Nerve Agent Auto-Injectors (ATNAA)

**Buyer:** DLA Troop Support
**Posted:** September 17, 2026
**Respond By:** October 02, 2026
**Identifier:** SPE2DP-26-D-0001
**NAICS:** 325412, 339112, 424210, 325414

The Defense Logistics Agency (DLA) Troop Support Medical in Philadelphia, PA is seeking information from qualified sources for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA) devices.
- Government Buyer:
  - Defense Logistics Agency (DLA) Troop Support Medical, Philadelphia, PA
- Products/Services Requested:
  - Antidote Treatment Nerve Agent Auto-Injector (ATNAA)
    - Dual-chamber auto-injector
    - Contains Pralidoxime Chloride Injection (300 mg/mL, 2 mL) and Atropine Injection (2.99 mg/mL, 0.7 mL)
    - Delivers 2.1 mg atropine and 600 mg pralidoxime chloride per injector
    - National Stock Number (NSN): 6505-01-362-7427
    - Must comply with MPID Number 6
    - FDA-approved for intramuscular administration
- Unique or Notable Requirements:
  - Product must be FDA-licensed
  - Respondents must provide product description, manufacturing capacity, and inventory information
  - DLA is interested in new or developmental products related to ATNAA, including those with independent laboratory or FDA testing
- OEMs and Vendors:
  - No specific OEMs or vendors are named; all capable manufacturers and distributors are encouraged to respond

### Description

<p><strong><u>Antidote Treatment Nerve Agent Auto-Injector</u></strong></p>

<p><strong><u>Request For Information (RFI)</u></strong></p>

<p>This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement.&nbsp;</p>

<p><strong>Item: </strong>ANTIDOTE TREATMENT, NERVE AGENT, Automatic, Dual-Chamber, Pralidoxime Chloride Injection, 300 mg per mL, 2 mL, and Atropine Injection, 2.99 mg per mL, 0.7 mL</p>

<p><strong>NSN:</strong> 6505-01-362-7427</p>

<p><strong>Description: </strong></p>

<p>The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA). ATNAA shall be made in accordance with MPID Number 6 dated May 2, 2019.</p>

<p>-----------------------------------------------------</p>

<p>The Defense Logistics Agency Troop Support is seeking sources capable of providing the Antidote Treatment Nerve Agent Auto-Injector (ATNAA).</p>

<p>The ATNAA shall be licensed by the Food and Drug Administration (FDA).&nbsp; Each auto-injector shall deliver 2.1 mg of atropine and 600mg of pralidoxime chloride in separate chambers, and be suitable for intramuscular administration. &nbsp;</p>

<p>Must have FDA approval to sell the ATNAA.</p>

<p>If your firm currently manufactures or distributes the ATNAA, please provide information with respect to the following:</p>

<p>a) Place of manufacture</p>

<p>b) Estimated annual capacity</p>

<p>c) FDA registration</p>

<p>d) Product name and description including description of any special features</p>

<p>e) Current unit sale price</p>

<p>f) Estimated inventory level and storage requirements</p>

<p></p>

<p>*** NEW PRODUCTS UNDER DEVELOPMENT***</p>

<p>For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc.&nbsp; Firms and organizations that currently develop or manufacture the ATNAA or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.</p>

<p>Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA.&nbsp; All information submitted shall remain with the U.S. Government and will not be returned.&nbsp; It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.</p>

<p>Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil</p>

[View original listing](https://sam.gov/opp/76ace4ad60f04dfda3210032a8e5b4cf/view)